Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
BACKGROUND
Restenosis after coronary interventions with stent implantation is still the main obstacle of interventional cardiology. The aim of this study was to compare a carbonized and high-grade stainless steel stent of identical design with regard to early and late adverse events.


METHODS
In this prospective randomized trial the carbonized MAC stent (amg GmbH, Raesfeld-Erle, Germany) was compared with the stainless steel MAC stent of identical design. Primary end point was diameter stenosis at follow-up; secondary end points were angiographic parameters, rate of restenosis, and major cardiac adverse events (MACE; myocardial infarction, reintervention, and death).


RESULTS
Between August 1999 and June 2002, 396 patients were randomized in 2 centers of Germany. Diameter stenosis at follow-up (38.6% +/- 23.4% vs 39.1% +/- 22.2%, P = .49) as primary end point, relative late lumen loss (26.8% +/- 23.7% vs 27.7% +/- 22.3%, P = .26), absolute late lumen loss (0.92 +/- 0.71 vs 0.92 +/- 0.66 mm, P = .58), net gain (1.4 +/- 0.8 vs 1.4 +/- 0.8 mm, P = .96), as well as restenosis rates (18.0% vs 19.0%, P = .81) and MACE (13.5% vs 12.2%, P = .71) were not significantly different between the carbonized and the pure stainless steel study arm, respectively.


CONCLUSIONS
The hypothesis of superiority of the carbonized stent over a stainless steel stent of identical design with regard to restenosis and MACE could not be proved. Inactive coating of stents seems to have no advantage over pure stainless steel stents, which was also demonstrated in other trials. The future probably lies in active coating of stents with drugs that reduce the neointimal proliferation process.
Sick
Peter B
PB
Department of Internal Medicine/Cardiology, Heart Center, University of Leipzig, Leipzig, Germany. sickp@medizin.uni-leipzig.de
Brosteanu
Oana
O
Ulrich
Matthias
M
Thiele
Holger
H
Niebauer
Josef
J
Busch
Ingmar
I
Schuler
Gerhard
G
D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001672:Biocompatible Materials; D002244:Carbon; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology; D004867:Equipment Design; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D013193:Stainless Steel; D015607:Stents; D013923:Thromboembolism / Q000517:prevention & control*; D019851:Thrombophilia / Q000188:drug therapy; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D001672:Biocompatible Materials; D013193:Stainless Steel; D002244:Carbon; D006493:Heparin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin